HeartLung Technologies proudly announces the newest addition to our Advisory Board, Dr. Robert A. Kloner, MD, PhD. With an illustrious career spanning over four decades and pioneering research in cardiovascular health, Dr. Kloner will play a key role in shaping our future initiatives. His expertise will help us continue to develop cutting-edge solutions for early detection of heart disease, lung cancer, osteoporosis, fatty liver, and other fatal conditions.
With over 45 years of experience, Dr. Kloner currently holds the positions of Chief Science Officer and Director of Cardiovascular Research at Huntington Medical Research Institutes (HMRI). His career includes esteemed roles at Northwestern University, Harvard Medical School, the University of Southern California, and recently, Caltech (The California Institute of Technology). He has made significant advancements in understanding heart disease pathophysiology, treatments, and the impact of environmental factors on cardiovascular health.
"Dr. Kloner's joining our advisory board marks a significant milestone for HeartLung. His vast knowledge and experience in cardiology will be invaluable as we continue to develop cutting-edge solutions for early detection and prevention of cardiovascular disease." - Dr. Morteza Naghavi, MD, founder of HeartLung Technologies and nonprofit SHAPE (Society for Heart Attack Prevention and Eradication).
At HeartLung Technologies, we are excited to benefit from Dr. Kloner's expertise in areas such as ischemic preconditioning, stunned myocardium, and the triggers of cardiovascular events. His collaborative approach and innovative mindset will drive our efforts to develop groundbreaking solutions for cardiovascular care.
"I am honored to be part of HeartLung's advisory board. I have known Dr. Naghavi for many years. He has assembled a very strong scientific leadership. Their commitment to preventing CVD and lung cancer through AI-enabled technologies is laudable and aligns perfectly with my lifelong work. I look forward to contributing to this critical mission." - Dr. Robert A. Kloner, MD, PhD, cardiologist and Professor of Medicine at the Keck School of Medicine at the University of Southern California and Director of Research at the Heart Institute of Good Samaritan Hospital in Los Angeles.
The addition of Dr. Kloner to HeartLung's advisory board is expected to accelerate HeartLung's progress in developing the groundwork for pivotal clinical trials. These clinical trials will pave the way to adopt new strategies for early detection and prevention of the number one and number two killers in the United States, heart disease and lung cancer.
An In-Depth Look at Dr. Robert A. Kloner’s Career and Achievements
Dr. Robert A. Kloner, MD, PhD, is Chief Science Officer and Director of Cardiovascular Research at Huntington Medical Research Institutes (HMRI). He has served as a Professor of Medicine at Keck School of Medicine at the University of Southern California (USC) since 1988 and was an attending cardiologist at Los Angeles County/ USC Medical Center for several decades. He was recently appointed as a Visiting Associate at the California Institute of Technology. Prior to accepting an appointment at HMRI, Dr. Kloner served as Director of Research at the Heart Institute of Good Samaritan Hospital in Los Angeles from 1987 to December 2014. He has run nationally and internationally known cardiovascular research programs for over 45 years, training dozens of medical scientists and collaborating with scores of physician-scientists, numerous research institutions, and medical industries worldwide.
In the 1970s, Dr. Kloner received his BS and MD in the Honors Program in Medical Education at Northwestern University and his PhD (Experimental Pathology) degree from Northwestern University Medical School, where he trained in the laboratory of Dr. Robert Jennings. Dr. Kloner is a member of the Alpha Omega Alpha honor society. He completed an internship and residency in internal medicine at Peter Bent Brigham Hospital and Harvard Medical School in Boston, Massachusetts (1975-1978). Additional training included clinical and research fellowships in medicine and cardiology (with Drs. Eugene Braunwald and Peter Maroko) at Harvard Medical School and Brigham and Women’s Hospital. He served as Assistant and then Associate Professor of Medicine at Harvard Medical School and was an attending cardiologist at Brigham and Women’s Hospital (1979-1984); in 1985, he joined the faculty as Professor of Medicine at Wayne State U. He was the recipient of an Established Investigator Award of the American Heart Association (AHA), is a fellow of the American College of Cardiology, an Inaugural Fellow of the Council on Basic Cardiovascular Sciences of the AHA, and was elected to the American Society of Clinical Investigation. In 2015 he was elected a Fellow of the Cardiovascular Section of the American Physiology Society.
Dr. Kloner has made major contributions to the understanding and treatment of heart disease, receiving funding from the National Institutes of Health (NIH), American Heart Association (AHA), Environmental Protection Agency (EPA), Department of Defense (DOD) and numerous corporations and private foundations. He performed some of the first studies on and helped define the concepts of no reflow in the heart (at Northwestern University), stunned myocardium, remote ischemic preconditioning, and triggers of cardiovascular events. He has made major contributions to the understanding of pathophysiology of heart attack (at Northwestern, Harvard University, Wayne State U, and USC) ; treatments for heart attack ( at Northwestern, Harvard and USC); triggers of cardiovascular events (USC); studies on high blood pressure and heart failure ( USC) ; the effect of toxins like alcohol, cocaine, and pollution on the heart; stem cell therapy for the heart (USC) ; the intersection between sexual dysfunction and cardiovascular disease (USC). His recent work at HMRI, funded by the NIH and Tobacco Related Disease Research Program studied the effects of e-cigarettes on the cardiovascular system. Dr. Kloner is also collaborating with a bio-engineering group (cell phone app) for noninvasive assessment of heart function ( USC, Caltech). A frequent contributor to the medical and scientific press, Dr. Kloner has authored or co-authored over 777 original papers in peer-reviewed journals, 222 chapters or monographs, and 578 abstracts (as of 2025). Dr. Kloner is the author and editor of 18 medical texts, including Cardiovascular Trials Reviews (10 editions), The Guide to Cardiology (3 editions), Stunned Myocardium, Ischemic Preconditioning, VIAGRA, and Heart Disease and Erectile Dysfunction. In addition, he has written and published three medical science fiction novels.
Among his editorial responsibilities, Dr. Kloner served as editor-in-chief of the Journal of Cardiovascular Pharmacology and Therapeutics (2009-2019). He has served as Guest Editor of Circulation. He is on the editorial boards of the American Journal of Cardiology, Basic Research in Cardiology, International Journal of Impotence Research, Journal of Cardiovascular Pharmacology and Therapeutics, Regenerative Medicine, and Life Sciences. Among his many career distinctions, Dr. Kloner has been listed in Who’s Who in America, The Best Doctors in America, and, in 2002, was cited by the Institute for Scientific Information as one of the most highly cited scientific authors. He has an H-index of 140 and is cited over 88,600 times. Dr. Kloner is a frequent lecturer at major scientific symposia including the Scientific Sessions of the American Heart Association, American College of Cardiology, and Transcatheter Cardiovascular Therapeutics Meetings, and he has lectured at most major academic medical centers in the United States. He has taught at both the Keck School of Medicine at USC and Caltech.
From Heart Science to Melodies
Beyond his scientific achievements, Dr. Kloner is also an awesome and talented pianist. His neo-classical piano album "Tunes from Edmonson Alley" reflects his artistic side. We invite you to explore his musical talents.
The full album is available on Spotify, Pandora, Apple Music, YouTube, and most streaming services.
Looking Ahead: Dr. Kloner’s Role at HeartLung Technologies
At HeartLung Technologies, we are delighted that Dr. Kloner has agreed to join our scientific leadership and help bring our innovative healthcare solutions to millions of people who need them to live longer and healthier lives.
Meet the visionary minds on HeartLung's Advisory Board and explore our exciting plans for 2025.
コメント